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Abstract
Background: The amount of data on protein-protein interactions (PPIs) available in public databases and in the
literature has rapidly expanded in recent years. PPI data can provide useful information for researchers in
pharmacology and medicine as well as those in interactome studies. There is urgent need for a novel
methodology or software allowing the efficient utilization of PPI data in pharmacology and medicine.
Results: To address this need, we have developed the ‘Druggable Protein-protein Interaction Assessment System’
(Dr. PIAS). Dr. PIAS has a meta-database that stores various types of information (tertiary structures, drugs/
chemicals, and biological functions associated with PPIs) retrieved from public sources. By integrating this
information, Dr. PIAS assesses whether a PPI is druggable as a target for small chemical ligands by using a
supervised machine-learning method, support vector machine (SVM). Dr. PIAS holds not only known druggable
PPIs but also all PPIs of human, mouse, rat, and human immunodeficiency virus (HIV) proteins identified to date.
Conclusions: The design concept of Dr. PIAS is distinct from other published PPI databases in that it focuses on
selecting the PPIs most likely to make good drug targets, rather than merely collecting PPI data.
Background
The importance of PPIs as targets for drugs, especially
small molecule drugs, has increased greatly in recent years
[1-4]. Over 30 PPIs have been widely studied as targets for
PPI-inhibiting small ligands. Currently, a huge amount of
PPI data has been rapidly accumulated in public databases
and in the literature. In addition, advances in high-
throughput experimental technologies have lead to a large
amount of various types of omics data, which have been
deposited in many databases. These PPI data and omics
data require methodologies for their application to phar-
macological and medicinal studies. There is an urgent
need to identify novel PPIs asd r u gt a r g e t sf r o mt h eP P I
data accumulated, since only about 30 druggable PPIs
have been well studied to date, whereas approximately
60,000 PPIs have been identified in human. We have
recently proposed integrative approaches for discovering
drug target PPIs by assessing the druggability of PPIs by
the use of various types of omics data [5,6]. The applica-
tion of our methods to human PPIs predicted many
potentially druggable PPIs.
Several databases and web-based tools specializing in
drug targets have been published. For example, TTD
[7,8], a database of known therapeutic target proteins,
stores information relevant to the targets, such as tertiary
structures, disease associations, pathways, and pertinent
l i t e r a t u r e .P D T D[ 9 ] ,ad a t a b a s ef o rin silico drug target
identification, stores diverse information on drug target
proteins identified by the web-based tool Target Fishing
Docking. SuperPred [10], a web-server for drug classifica-
tion, uses a similarity score between drugs/chemicals to
predict drug target proteins. These drug target databases
and web-servers are very useful for researchers in in silico
pharmacology and medicine. All of them, however, deal
only with single proteins, rather than PPIs.
Recently, two databases (2P2IDB [11] and TIMBAL
[12]) specializing in drug target PPIs and PPI-inhibiting
chemicals have been published. 2P2IDB mainly focuses on
protein/protein and protein/inhibitor interfaces in terms
of various physicochemical parameters such as atom and
residue properties, pocket volume, and accessible surface
area [11]. TIMBAL is a database of small molecules that
inhibit protein/protein complexes, and it stores many
properties of the molecules such as molecular weight,
LogP value, number of rings, number of rotatable bonds,
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vide useful information to researchers developing PPI
inhibitors. Both databases, however, contain only known
drug target PPIs, so only a very small number of PPIs
and PPI-inhibiting chemicals are stored. As a next step,
in order to efficiently utilize the databases such as 2P2IDB
and TIMBAL, it is needed to apply the information
obtained from known drug target PPIs and their inhibi-
tors to other PPIs not presently targeted by inhibitors.
Here we describe a novel database system, Dr. PIAS,
which focuses on the druggability of PPIs. Dr. PIAS
assesses the druggability of PPIs, currently not targeted
by inhibitors, by utilizing the information obtained from
known drug target PPIs. Dr. PIAS holds not only known
drug target PPIs but also all PPIs identified to date for
human, mouse, rat, and HIV proteins. In addition to
information on the properties of the tertiary structures
of PPI interfaces and that on the properties of drugs/
chemicals related to interacting proteins, which are dealt
with in 2P2IDB and TIMBAL, other properties associated
with the biological function of PPIs are also included in
the assessment. This is important because, to select a
drug target PPI, a researcher considers not only infor-
mation on the tertiary structure of the PPI and its
known inhibitors but also that on the biological function
of the PPI. All information on the PPIs used in the
assessment is stored in Dr. PIAS. Users can search for
druggable PPIs in Dr. PIAS by using various words and
terms such as protein/gene name, tertiary structure, dis-
ease, pathway, and drug/chemical name as keywords.
Construction and context
Assessing the druggability of PPIs
The most distinctive characteristic of Dr. PIAS is that
the system assesses the druggability of PPIs by our origi-
nal SVM-based method [6]. Thirty known drug target
PPIs, including IL2/IL2RA, MDM2/TP53, and BCL2/
BAK1, serve as the positive instances (Additional file 1:
Table S1). These PPIs were selected from review articles
focusing on druggable PPIs [1-4,13-15]. Positive
instances must satisfy both the following two criteria.
￿ A PPI-inhibiting small chemical has been identi-
fied, and its potency as a PPI inhibitor has been vali-
dated by in vitro and/or in vivo assays.
￿ A binding pocket for the PPI-inhibiting small che-
mical has been located on the tertiary structure of a
protein, and it overlaps with the PPI interface.
Structural, drug/chemical, and functional attributes
(Additional file 1: Table S2) of the positive instances
and other PPIs in Dr. PIAS (test instances) were calcu-
lated and stored in Dr. PIAS. We used these attributes
for our SVM-based method [6]. The program package
Libsvm [16] was used for SVM.
In previous study, we have obtained the best SVM
model for discriminating the positive and negative
instances, when the radial basis function kernel and the
ratio of positives:negatives = 1:1 were used in machine
learning by SVM [6]. The cross validation test using the
best model showed the accuracy of 80.5% (sensitivity,
81.6%; specificity, 79.4%) that was comparable to the
values of accuracy in previous studies on drug target
prediction [6]. Also in Dr. PIAS, we adopt this SVM
model for the assessment of the druggability of PPIs.
We defined ‘druggability score’ to quantitatively assess
the druggability of PPIs [6]. Druggability score is based
on the results of our SVM-based method (Figure 1). To
conduct machine learning by SVM, we created training
data from the positive and negative instances. The ratio
of positives to negatives was set as 1:1. The negative
instances were randomly chosen from the test instances,
positive instances
test instances
10000 random
training data
negative instances
positive instances
negative instances
positive instances
negative instances
positive instances
negative instances
positive instances
…
learning
learning
learning
learning
…
test instances
E/F
...
C/D
A/B
# times judged
to be positive
instance (PPI)
...
9999/10000
8500/10000
7000/10000
‘druggability score’
Figure 1 Definition and calculation method of ‘druggability score’. The flow chart of calculating ‘druggability score’ by our SVM-based
method is schematically illustrated. For details, see text.
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‘negative’.I nt h i ss t u d y ,‘negative’ PPI can be PPI for
which there is no chemical that inhibit the PPI. We can-
not be certain at present that a small chemical inhibiting
t h eP P Iw i l ln o tb ed i s c o v e r e di nf u t u r es t u d i e s .T o
avoid any bias in choosing the negatives from the test
instances, we created 10,000 random training data sets.
To predict novel druggable PPIs, the SVM models
trained by each of the 10,000 random training data sets
were applied to the test instances. We counted the
number of times an instance (or a PPI) was judged to
be positive in the 10,000 training-prediction iterations.
This number was divided by 10,000 and then was
defined as the druggability score. The scores range from
0 (non-druggable) to 1 (highly druggable). For example,
the score of 0.9999 of a PPI indicates that the PPI is
judged to be positive by the 9,999 SVM models of the
10,000 models and that the PPI is predicted as ‘highly
druggable’ (Figure 1). Because the negative instances are
randomly chosen from the test instances, it is highly
probable that negatives of one training data are com-
posed of PPIs similar to the positives, while those of
another training data are composed of PPIs dissimilar to
the positives. A high druggability score of a PPI means
that the PPI is similar to the positives, no matter what
type of PPIs constitutes the negatives. Thus, the higher
the score of a PPI, the more likely the PPI has attributes
similar to those of the positive instances (known drug
target PPIs).
Data sources of PPIs
The PPI data stored in Dr. PIAS were retrieved from
public sources [17,18] and from several studies on the
identification of human PPIs by high-throughput experi-
mental assays [19-21] (Table 1). As of 2010/12, Dr.
PIAS contains 71,500 PPIs. Most of these PPIs (63,010/
71,510; 88%) are between human proteins (Table 2).
The number of PPIs between mouse proteins (3,331)
and those between human and HIV proteins (2,295) fol-
lows that of human PPIs. As shown below, Dr. PIAS has
a meta-database that stores various types of information
(tertiary structures, drugs/chemicals, and biological
function associated with PPIs) retrieved from public
sources (Table 3).
Structural information
Several properties of PPIs stored in Dr. PIAS were pre-
calculated using our original and several freely available
computational algorithms/programs. Among the proper-
ties of PPIs, those based on tertiary structure are the
most important for in silico drug design and
Table 1 Data source of PPIs stored in Dr. PIAS
Data source Number of PPIs Reference
Entrez Gene 57,570 [17]
Ramani et al. (2008) 6,937 [21]
Genome Network Platform 5,528 [18]
Stelzl et al. (2005) 3,164 [19]
Lim et al. (2006) 2,296 [20]
Total number of non-redundant PPIs 71,500
Table 2 Number of PPIs from each species stored in
Dr. PIAS
Species Number of PPIs
Human 63,010
Mouse 3,331
HIV
a 2,295
Rat 870
Others 1,994
aPPIs between human and HIV proteins.
Table 3 Information stored in Dr. PIAS
Information Source(s) or
program(s) used
Structural information
Tertiary structures [22-24]
Pockets on PPI interface [25]
Volume [6,25]
Accessible surface area [6,25]
Compactness [6]
Planarity [6]
Narrowness [6]
Curvature [26]
Roughness [26]
Amino acid composition [6,24,25,27]
Domains [28,29]
Disordered regions [37]
Amino acid sequence motifs [38,39]
Drug/chemical information
FDA-approved drugs [40]
Chemicals associated with interacting
proteins
[41]
Functional information
Human diseases in OMIM [42]
Number of interacting proteins in PPI
network
[6]
Biological pathways [43,44]
GO terms and identity scores of GO
terms
[6,45]
Gene expression profiles and similarity
scores of profiles
[6,46]
Paralogs [43,47]
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of the protein/protein complex of a PPI had been
already solved. Amino acid sequence similarity searches
using the computational program BLASTP [22] were
conducted against the PDB database [23]. If both the
two interacting proteins showed sequence identities of
≥80% to distinct polypeptide chains in the same PDB
entry, and the two chains physically contact each other
in the tertiary structure of the protein/protein complex,
the PDB entry was considered to be the tertiary struc-
ture of the PPI. Whether two chains physically contact
was checked by consulting the PPI interface information
in the PDBsum database [24].
If the tertiary structure of a PPI had been already solved,
we further detected potential ligand-binding pockets that
overlap with the PPI interface by using the alpha site
finder implemented in the software package Molecular
Operating Environment [25]. Physicochemical and shape
properties of the pockets were calculated and stored in
our database (Table 3). Planarity, narrowness, and rough-
ness of the pockets were originally defined by us [6,26].
These properties and compactness, curvature, and amino
acid composition of the pockets were calculated by using
computational programs/algorithms written by us [6,26].
Other properties were calculated by using the Molecular
Operating Environment or obtained from the results of
the computational program DSSP [27].
We retrieved information on protein domains from
the Pfam database [28] and detected domains responsi-
ble for PPIs by consulting the iPfam database [29]. Lists
of the interacting domain pair(s) and domains of each
interacting protein are stored in our database.
Recent studies have revealed that, in some groups of
PPIs, disordered regions of proteins and amino acid
sequence motifs in these regions are responsible for
PPIs [30-33]. Among the PPIs used in the positive
instances in our SVM-based method, interfaces of some
PPIs such as BCL2/BAK1, BIRC4/CASP9, and MDM2/
TP53 are formed by interaction between an ordered
region in one protein and a disordered region in the
other protein. Disordered regions in BAK1, CASP9, and
TP53 in monomer changed to ordered state when pro-
tein/protein complex is formed [34]. Some chemicals
inhibiting these PPIs mimic sequence motifs in the dis-
ordered regions [34-36]. We predicted disordered
regions using the computational program POODLE-L
[37] and retrieved the information on sequence motifs
from the ELM database [38]. If the number of
‘instance’s of a motif in ELM was ≥2, we manually
made a multiple alignment of the instances, and then
created a hidden Markov model profile by using the
computational program HMMER [39]. Using the hidden
Markov model profiles, the motifs were predicted for
each protein by the HMMER. Lists of the motifs and
disordered regions predicted by the programs are stored
in our database.
Drug/chemical information
In several of the known target PPIs such as ESR1/
NCOA2 and GRB2/EGFR, one interacting partner
(ESR1 and EGFR) is a druggable protein that has been
already targeted by a drug approved by the United
States Food and Drug Administration (FDA). Several
other known target PPIs are novel drug targets, and
both interacting partners have no FDA-approved drug
targeting them. In our SVM-based method, we used the
number of drugs as the PPI attributes to assess whether
the fact that an interacting protein has been already tar-
geted by existing drugs influences the selection of PPIs
as drug targets. The information on the FDA-approved
drugs was retrieved from the DrugBank database [40].
The number of drugs targeting each interacting partner
protein of a PPI was counted and stored in our database
together with lists of drugs.
The information on chemicals that experimentally
assayed for the activity to each of the two interacting
proteins was retrieved from the ChEMBL database [41].
Functional information
Information on human diseases caused when a protein
is heritably or somatically mutated is essential for asses-
sing the druggability of the protein. We retrieved infor-
mation on human diseases from the OMIM database
[42]. When using the information in our SVM-based
method, it was transformed to a score of 0 or 1 [6]. The
information is scored as 1 if both two interacting pro-
teins of a PPI are implicated in OMIM-registered dis-
eases (not limited to the same disease). The attribute is
scored as 0 if only one interacting protein is implicated
in a disease or if neither interacting protein is implicated
in diseases. Lists of diseases associated with each inter-
acting protein are stored in our database.
To repress a disease state with drugs, it would be
desirable in some cases to target the proteins that func-
tion as ‘hubs’ in a PPI network. In other cases, targeting
proteins that function in a peripheral part of a network
c o u l db em o r ef e a s i b l ef o rt h et r e a t m e n to fad i s e a s e .
After the PPI network was constructed based on the PPI
data stored in Dr. PIAS, the number of all interacting
proteins for each partner of a PPI was counted and
stored in our database.
As with the number of interacting proteins, proteins
that function in a large number of biological pathways
may be more desirable targets for therapeutic
intervention for some diseases, while proteins
involved in a limited number of pathways may be
more desirable targets for other diseases. We
retrieved information on biological pathways from the
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number of pathways in which a protein is involved
and stored these numbers in our database together
with lists of pathways.
To assess the degree of similarity in biological func-
tion of the two interacting proteins, we utilized Gene
Ontology (GO) [45]. GO terms assigned to proteins in
Dr. PIAS were retrieved from the GO database [45].
Based on the GO terms, we calculated the identity
scores of GO terms between the two interacting pro-
teins according to equation S3 in Additional file four in
[6]. The identity scores and lists of GO terms assigned
to each protein are stored in our database.
For a protein to be selected as a drug target, it is
advantageous if the protein functions in a limited
number of tissues/organs including the tissues/organs
that develop the disease. Because of a scarcity of infor-
m a t i o no np r o t e i ne x p r e s s i o np r o f i l e si nh u m a n ,w e
utilized gene expression profiles. Information on gene
expression profiles was retrieved from the UniGene
database [46]. To assess the degree of similarity
between the gene expression profiles of the two inter-
acting proteins in a PPI, we calculated the similarity
scores of expression profiles between the two genes
according to equation S4 in Additional file 4 in [6].
The similarity scores and gene expression profiles are
stored in our database.
The number of paralogs is an important factor in
order for a protein to be selected as a drug target, since
the researchers must consider potential adverse effects
caused by the drug binding to non-target paralogs. Tar-
get proteins with a large number of paralogs may be
associated with more severe adverse effects. The infor-
mation on paralogs was retrieved from the KEGG and
PIRSF [47] databases. We stored the number of paralogs
of each protein and lists of paralogs in our database.
Druggable Protein-proteinInteraction Assessment System
Simple search:
Youcan search with ...
Entrez Gene ID,
Entrez Gene name(including
synonyms),
UniGene ID,
UniProt ID,
UniProt entry name(including
synonyms),
Pfam ID,
Pfam entry name,
PDB ID,
ELM identifier,
Gene Ontology term/ID,
OMIM disease,
KEGG pathway,
DrugBank ID, or
drug name.
About 'Dr. PIAS'
'Druggable Protein-protein Interaction Assessment System' (Dr. PIAS) is a system for assessing the
druggability of protein-protein interactions (PPIs). Various types of information on tertiary structures, drugs
and chemicals, and biological function associated with PPIs retrieved from public databases are stored as a
database in Dr. PIAS. The database in Dr. PIAS also stores various properties of PPIs investigated by some
freely-available and our original computational algorithms/programs. By utilizing this information, Dr. PIAS
assesses the druggability of PPIs with a supervised machine-learning method, support vector machine (see
Help). In this version, Dr. PIAS contains about 50,000 PPIs mainlyof human, mouse, rat, bovine, and
Xenopus proteins. The PPI data were retrieved from the public databases and some previous studies on the
identification of human PPIs by high-throughput experimental technologies.
You can search Dr. PIAS for various keywords (protein/gene names, tertiary structures, diseases, pathways,
chemicals, and etc) in which you are interested. By iterating the search with the additional other keywords, you
can select candidates of druggable PPIs that are more promising as drug targets in a research area (e.g.,
disease, pathway, or protein family) onwhich you focus.
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Advanced search -search by terms or phrases-
Enter terms or phrases in each box.
(Pleas e do not use boolean operators such as'AND', 'OR',and 'NOT'.)
Protein or Gene ID/Name: (e.g., MDM2, "mouse double minute 2", Hs.567303, Q00987)
Pfam: (e.g., SWIB, PF02201)
PDB: (e.g., 1ycr)
ELM: (e.g., LIG_MDM2)
DrugBank: (e.g., DB02872, EXPT01878, "Mdm2 inhibitor")
OMIM: (e.g., "tumor formation", MDM2)
KEGG PATHWAY: (e.g., Glioma)
Gene Ontology(terms): (e.g., "ubiquitin-protein ligase activity", GO:0004842)
Enter numerical numbers in each box.
DrugBank(# drugs) (click to expand)
Gene Ontology(identity score) (click to expand)
Gene Expression(similarity score) (click to expand)
PPI network conectivity (click to expand)
Check boxes if you specify gene expression pattern.
UniGene gene expression(Health State) (click to expand)
UniGene gene expression(Body Sites) (click toexpand)
UniGene gene expression(Developmental Stage) (click to expand)
Other search options.
heterodimer or homodimer
3D structures of protein complexes: solved or not solved
species: all species
Select whether you draw PPI network image or not.
Draw PPI network (time-consuming!!) Do not draw PPI network
Reset Search
Search result
41PPI(s) hit
PPI network
Legend to PPI network
Nodes shown by diamond ( ) represent
proteins that are registered as drug
targets in theDrugBank database.
Nodes filled with lightbrown represent
proteins that are registered as disease-
related ones in the OMIM database.
Nodes encircled with thick line
represent proteins that have similar 3D
structure(s) in the PDB database.
Size of a node is approximately
proportional to the number of
interacting partner proteins in Dr. PIAS.
Edges shown by thick line indicatethat
3D structure(s) of the protein complex
is registered inthe PDBdatabase.
Edges are coloredaccording to the
druggability score assessed by using all
PPI attributes.
[Download PPI list as SIF file]
SIF file can be used as input file to the
network-drawing software Cytoscape .
druggability score
Summary table 0.99 < 0.99& 0.90 < 0.90& 0.80 < 0.80& 0.70
Interactor A Interactor B
Asse ssment of
the druggability by SVM
69 25 ABL1 9606 Hs.431048 P00519 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 15657060 0.7078 0.9723
1425 317 APAF1 9606 Hs.708112 O14727 842 CASP9 9606 Hs.329502 P55211 Entrez Gene
9390557
9488720
9539746
11113115
15262985
9837928
10376594
15829969
0.1404 0.8063 0.489 0.2086
1549 329 BIRC2 9606 Hs.696238 Q13490 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 9545235 0.6306 0.9985
1573 330 BIRC3 9606 Hs.127799 Q13489 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 9545235 0.6306 0.994
1605 331 XIAP 9606 Hs.356076 P98170 842 CASP9 9606 Hs.329502 P55211 Entrez Gene
9545235
11390657
15280366
16189514
11927604
15300255
0.2784 0.9353 0.9966 0.8768
1630 332 BIRC5 9606 Hs.514527 O15392 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 11069302 0.6306 0.9771
3241 598 BCL2L1 9606 Hs.516966 Q07817 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 9539746 0.6306 0.998
4543 834 CASP1 9606 Hs.2490 P29466 22900 CARD8 9606 Hs.446146 Q9Y2G2 Entrez Gene 11821383 0.7953 0.2161
4557 835 CASP2 9606 Hs.368982 P42575 842 CASP9 9606 Hs.329502 P55211 Entrez Gene 11832478 0.6306 0.9758
≥≥≥≥
Pocket information
pocket No. 1nw9_A 1 1nw9_A 2 1nw9_A 3 1nw9_B 1 1nw9_B 3
A
B
C
D E
Figure 2 Screenshots of Dr. PIAS.( A )T o pp a g eo fD r .P I A S .( B )‘Advanced search’ form. (C) Main search result summarizing PPIs and their
druggability scores. (D) PPI network derived from a search result of Dr. PIAS. The network is drawn using the software eXpanda [48]. (E) Example
of potential ligand-binding pocket on a PPI interface, which was used for assessing the druggability of a PPI. The pocket is shown by atoms
colored red. The image is generated using the software Jmol [49]. (To see the pocket information, click the header ‘structural information’ in the
main search result table, then click the header ‘# protein complexes in PDB’ in the ‘Structural information’ table in a new window/tab opened,
and then click ‘[pocket]’ after the list of PDB entry names in the ‘PDB information’ table in a new window/tab opened.).
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tional database (MySQL).
Utility
User interface
Screenshots of Dr. PIAS are shown in Figure 2.
Figure 2A shows a top page from Dr. PIAS. Using the
‘Advanced search’ form of Dr. PIAS (Figure 2B), users
can search for druggable PPIs in Dr. PIAS by inputting
various keywords and terms (protein/gene names, ter-
tiary structures, domains, motifs, diseases, pathways, GO
terms, gene expression patterns, drug/chemical names,
identifiers of public databases, etc). Users can also use
the amino acid sequence of a protein as a query. Amino
acid sequence similarity search is performed by the
BLASTP program, and then PPIs of the query protein
and those of homologs of the query are listed as a
search result.
Figure 2C shows a main search result summarizing
PPIs and their druggability scores. The columns of the
druggability score are colored depending on the score
(≥0.99, red; <0.99 and ≥0.9, magenta; <0.9 and ≥0.8, hot-
pink; <0.8 and ≥0.7, pink). The threshold of the coloring
of ≥0.9 (red and magenta) is set based on the average
value of the druggability scores of the positive instances
(known drug target PPIs) used in the druggability
assessment (see Figure 5 in [6]). Other thresholds are
set arbitrarily. The assessment of the druggability of
PPIs is conducted in four ways: three of the four use
only the structural, drug/chemical, or functional attri-
butes of the PPIs, respectively, while the fourth uses all
attributes in our SVM-based method (Additional file 1:
Table S2). These four ways correspond to the four col-
umns of the druggability score in Figure 2C.
If a user selects the ‘Draw PPI network’ radio button
in the ‘Advanced search’ form, a PPI network derived
from the search result is drawn by the computational
program eXpanda [48] (Figure 2D). Nodes and edges of
the network represent proteins and PPIs, respectively.
The PPI network reflects information stored in
Dr. PIAS. If the tertiary structure of the protein/protein
complex of a PPI has been solved, the edge representing
the PPI is shown as a thick line. Edges of the network
are colored according to the druggability score (calcu-
lated using all attributes). The size of the nodes is
approximately proportional to the number of interacting
partner proteins in Dr. PIAS. Nodes circled with a thick
line represent proteins whose tertiary structures (but
not necessarily those of the protein/protein complex)
have been already solved. Nodes colored lightbrown
represent proteins that are registered as disease-
implicated in OMIM. Nodes shown by a diamond shape
indicate proteins registered as known drug targets in
DrugBank.
By clicking the headers of the summary table shown
in Figure 2C, users can see details of the information
stored in Dr. PIAS. Figure 2E is an example of the level
of detail regarding a potential ligand-binding pocket on
a PPI interface, which is used for assessing the drugg-
ability of a PPI. The pocket is shown by atoms colored
red. The image was generated by using the software
Jmol [49].
Case studies
In this section, the usage of Dr. PIAS is illustrated by
applying it to search for potentially druggable PPIs from
two points of view: one is from a disease point of view
and the other is from a protein.
Searching for druggable PPIs implicated in lung cancer
Lung cancer is one of the most common cancers in
both men and women worldwide [50]. Many studies to
develop drugs for the treatment of lung cancer have
been conducted both in the pharmaceutical industry
and in academia, but only a few drugs have been
approved by the FDA [51,52]. The identification of
n o v e ld r u gt a r g e t sf o rl u n gc a n e rw o u l dp r o m p tt h e
development of drugs targeting this cancer.
When using Dr. PIAS, users can easily set versatile
criteria to search for druggable PPIs. To search for PPIs
that are potentially druggable for lung cancer, we set the
following criteria (Figure 3).
￿ A PPI is derived from human.
￿ The PPI is involved in biological pathways asso-
ciated with lung caner.
￿ Genes coding interacting proteins are expressed in
lung cancer cells.
￿ Tertiary structure of the protein complex of the
PPI has been solved.
The last criterion is intended to search for PPIs that are
more amenable to in silico drug design and development.
If a user does not intend to design and develop drugs by
in silico technologies, this criterion is superfluous. In
total, 116 PPIs satisfy all the above criteria (Additional
file 1: Table S3). The PPI network in Figure 4, drawn
from the search result, shows that 17 PPIs in the network
are assessed as highly druggable (druggability score ≥0.9,
edges colored magenta) (Table 4).
Among the 17 PPIs, GRB2/VAV1 has the highest
score of 0.9662 when all attributes were used for the
assessment. Figure 5 shows that 3 pockets were detected
on GRB2/VAV1 interface and one of them (pocket No.
1 on 1GCQ_C polypeptide chain) has the highest score
of 0.7141 when only structural attributes were used for
the assessment. Compared with amino acid frequencies
on the total surface of the protein, the pocket with the
highest score are enriched in glutamic acid,
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Page 6 of 12phenylalanine, histidine, and tryptophan that are fre-
quently observed as hot spots on PPI interfaces [53,54].
The accessible surface area (736Å
2) of this pocket is the
largest among the three pockets, and the volume
(314.62Å
3) is the second largest. GRB2 protein is a well-
studied drug target [55]. One FDA-approved drug
[DrugBank:DB00061] exists targeting GRB2, and 365
chemicals (as of 2010/12) experimentally assayed for the
activities to GRB2 are registered in ChEMBL. In con-
trast, there is no approved drug and experimentally
Advanced search -search byterms or phrases-
Enter terms or phrases in each box.
(Please do not use boolean operators such as 'AND', 'OR', and 'NOT'.)
Protein or Gene ID/Name: (e.g., MDM2, "mouse double minute 2", Hs.567303, Q00987)
Pfam: (e.g., SWIB,PF02201)
PDB: (e.g., 1ycr)
ELM: (e.g., LIG_MDM2)
DrugBank: (e.g., DB02872, EXPT01878, "Mdm2 inhibitor")
OMIM: (e.g., "tumorformation", MDM2)
KEGG/PID PATHWAY: " lung cancer" (e.g., Glioma)
Gene Ontology(terms): (e.g., "ubiquitin-protein ligase activity", GO:0004842)
Enter numerical numbers in each box.
DrugBank(# drugs)(click to expand)
Gene Ontology(identity score) (click to expand)
Gene Expression(similarityscore) (click to expand)
PPI network conectivity (click to expand)
Check boxes if you specify gene expression pattern.
UniGene gene expression(Health State) ( c l i c kt oe x p a n d )
expressed in ...
adrenal tumor bladder carcinoma breast tumor cervical tumor chondrosarcoma
colorectal tumor esophageal tumor gastrointestinal tumor germ cell tumor glioma
head and neck tumor kidney tumor leukemia liver tumor lung tumor
lymphoma nonneoplasia normal ovarian tumor pancreatic tumor
primitive neuroectodermal tumor of the CNS prostate cancer retinoblastoma skin tumor
soft tissue/muscle tissue tumor uterine tumor
adrenal tumor bladder carcinoma breast tumor cervical tumor chondrosarcoma
colorectal tumor esophageal tumor gastrointestinal tumor germ cell tumor glioma
head and neck tumor kidney tumor leukemia liver tumor lung tumor
lymphoma nonneoplasia normal ovarian tumor pancreatic tumor
primitive neuroectodermal tumor of the CNS prostate cancer retinoblastoma skin tumor
soft tissue/muscle tissue tumor uterine tumor
UniGene gene expression(Body Sites) (click to expand)
UniGene gene expression(Developmental Stage) (click to expand)
Other search options.
heterodimeror homodimer
3D structures of protein complexes: solved or not solved
species:
Select whether you drawPPI network image or not.
Draw PPI network (time -consuming!!) Do not draw PPI network
not expressed in ...
1) Input “lung cancer”
in the ‘KEGG/PID
PATHWAY’ box.
2) check the ‘lung
tumor’ box in the
‘expressed in ...’o f
the ‘UniGene gene
expression (Health
State)’.
3) select the ‘solved’
radio button of the
‘3D structures of
protein complexes’.
4) select the ‘human’
from the ‘species’ pull-
down menu.
5) select the ‘Draw PPI
network’ radio button.
Figure 3 Searching for PPIs implicated in lung cancer. In the ‘Advanced search’ form of Dr. PIAS, 1) input ‘“ lung cancer”‘in the ‘KEGG/PID
PATHWAY’ box, 2) check the ‘lung tumor’ box in the ‘expressed in..’ part of the ‘UniGene gene expression (Health State)’, 3) select the ‘solved’
radio button of the ‘3 D structures of protein complexes’, 4) select the ‘human’ from the ‘species’ pull-down menu, and 5) select the ‘Draw PPI
network’ radio button.
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Page 7 of 12assayed chemical for VAV1 protein. Chemicals inhibit-
ing GRB2/VAV1 PPI have not been reported, thus this
PPI is a novel drug target.
Interestingly, the list of PPIs in Table 4 includes EGFR/
TGFA, and the PPI has a high druggability score of
0.9393. TGFA is a member of the EGF family, and has a
tertiary structure similar to EGF. TGFA forms a protein/
protein complex with EGFR in a manner similar to
EGFR/EGF complex [56]. EGFR/EGF PPI is the target for
the FDA-approved anti-EGFR antibody, cetuximab, for
the treatment of several cancers such as colorectal cancer
and head and neck cancer [51,52]. EGFR/EGF is assessed
as highly druggable by our method in three of the four
assessments. A druggability score of 0.8712 is obtained
when only structural attributes are used, whereas a score
of 0.9997 is obtained when functional attributes are used,
and a score of 0.8724 when all attributes are used (Addi-
tional file 1: Table S3). Thus, EGFR/TGFA may be a drug
Figure 4 PPI network related to lung cancer. The network is drawn from the search result obtained from the criteria in Figure 3. Edges (PPIs)
are colored according to their druggability scores (≥0.99, red; <0.99 and ≥0.9, magenta; <0.9 and ≥0.8, hotpink; <0.8 and ≥0.7, pink). For details
of the coloring and shape of the nodes and edges, see text.
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Page 8 of 12target for cancers including lung cancer. In Table S3,
another PPI, ERBB2(HER2)/ERBB2(HER2), which has
been already targeted by a FDA-approved drug, is
included. The anti-HER2 antibody, trastuzumab, has
been developed for the therapeutic intervention of breast
cancer [51,52]. Although these FDA-approved drugs,
cetuximab and trastuzumab, are not small molecule
drugs, these results indicate that Dr. PIAS is effective in
predicting druggable PPIs. PPIs in Table 4 other than
GRB2/VAV1 and EGFR/TGFA may be potential drug
targets for lung cancer in future studies.
Searching for druggable PPIs associated with BCL-XL
As described in the former section, 2P2IDB and TIM-
BAL have been already published that hold drug target
PPIs and their inhibitors. By using an identical protein
as a query when searching for druggable PPIs in Dr.
PIAS and the two databases, we demonstrate the
differences and similarities in output results obtained
from the three databases.
BCL-XL protein was adopted as a query. The PPIs of
BCL-XL with BAX, BAK, and BID proteins are well-stu-
died drug target PPIs [35], and both 2P2IDB and TIMBAL
contain the PPIs. From 2P2IDB, a user can obtain the
information on 8 tertiary structures (as of 2010/12) of
BCL-XL/BAK protein/protein and BCL-XL/inhibitor
complexes and the information on various physicochem-
ical properties of the inhibitor-binding pockets. If a user
search for BCL-XL in TIMBAL, the user can obtain the
information on 26 chemicals (as of 2010/12) inhibiting
the PPIs of BCL-XL with BAX, BAK, and BID. The two
databases provide users with the structural and drug/che-
mical information on already-studied drug target PPIs.
When a user use the protein name ‘BCL2L1’ (a syno-
nym of BCL-XL) as a keyword in searching Dr. PIAS,
the user can obtain 66 PPIs (as of 2010/12) of BCL-XL
1gcq_BC 1gcq_B 1 0 0 2.44444 0 3.66663 0 0 0 0 0 0 0 1.83334 0 1.8333 0 0 0 0 3.66663 136.62 415 0.105
1gcq_BC 1gcq_C 1 1.3 0 0 1.48572 1.73334 0 1.73334 0 2.59997 0 0 1.3 0 0 0 0 0 0 5.20003 0 314.62 736 0.173
1 g c q _ B C 1 g c q _ C 2 0 0 0000 00 6 . 4 9 9 9 2 0 1 2 . 9 9 9 8 0 1 . 8 5 7 1 5 0 00 0 0 06 . 4 9 9 9 2 3 2 4 . 8 8 3 6 2 0 . 0 8 5
[Download summary table as Excel file]
037
299
237
4
1gcq_BC 1gcq_B 1
1gcq_BC 1gcq_C 1
1gcq_BC 1gcq_C 2
.329 05 0.545963 4.39546 0.115116 8.55856 0.036689 0.040021 0.0449
0.427473 0.462913 8.62699 0.223409 12.4478 0.114326 0.275839 0.74 1
0.897459 0.485922 5.1015 0.622918 3.74134 0.188516 0.112753 0.0412
0
3
2
  	

 	 	
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Figure 5 Physicochemical and shape properties of the potential ligand-binding pockets located on GRB2/VAV1 PPI interface.T h r e e
pockets were detected on the interface of GRB2/VAV1 complex [PDB:1GCQ]. The physicochemical and shape properties of the pockets are
shown. These properties were used for the assessment of the druggability. For the definition and details of the properties, see [6,26]. The
druggability scores calculated are shown in the column named ‘assessment by SVM’. The pocket No. 1 identified on 1GCQ_C polypeptide chain
has the highest score of 0.7431 (see Table 4). The location of this pocket is illustrated using the Jmol. In the illustration, the polypeptide chain
1GCQ_B is colored lightblue and 1GCQ_C is gray. The atoms constituting the pocket are colored red.
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Page 9 of 12with many other proteins as well as with BAX, BAK,
and BID (Additional file 1: Table S4). Distinct from
2P2IDB and TIMBAL, Dr. PIAS assesses the druggability
of all PPIs associated with BCL-XL as well as already-
studied drug target PPIs and provides structural, drug/
chemical, and functional information on all PPIs.
Among the 66 PPIs, 5 PPIs (BAD/BCL2L1, BAK1/
BCL2L1, BCL2L1/BCL2L1, BCL2L1/BCL2L11, and
BCL2L1/Bcl2l11) have the tertiary structures of protein/
protein complexes in the PDB, and the druggability
assessments were conducted in all four ways (Additional
file 1: Table S4). BAK1/BCL2L1 has the highest drugg-
ability score of 0.7674 when all attributes were used for
the assessment. Like 2P2IDB,t h ei n f o r m a t i o no nt h e
physicochemical and shape properties of the ligand-
binding pocket on BAK1/BCL2L1 PPI interface can be
obtained from Dr. PIAS (Table 3). Like TIMBAL, a user
can obtain the drug/chemical information from Dr.
PIAS. Unlike 2P2IDB and TIMBAL, Dr. PIAS provide a
user with the information on biological function of
BAK1 and BCL2L1 proteins (Table 3). BCL2L1 is
involved in apoptosis pathway, focal adhesion pathway,
and some cancer-related pathways (based on KEGG).
BAK1 functions as a direct p53 effector (based on PID).
T h eg e n ee n c o d i n gB C L 2 L 1i se x p r e s s e di nm a n yb o d y
sites (34/44 in UniGene). The gene encoding BAK1 is
also the case (32/44 in UniGene). In PIRSF, BCL2L1 has
10 paralogs, while BAK1 has 5 paralogs. In addition to
the structural and drug/chemical information, the func-
tional information described above can be also helpful
for a researcher to select drug target PPIs.
Discussion
Comparisons with existing databases
Currently, there exist two databases (2P2IDB and TIM-
BAL) that focus on drug target PPIs. These databases
hold known drug target PPIs and their inhibitors. In
contrast, Dr. PIAS holds all PPIs of human, mouse, rat,
and HIV proteins identified to date as well as known
drug target PPIs. For each PPI, we assessed the drugg-
ability by the SVM-based method by using structural,
drug/chemical, and functional attributes of the PPIs.
These two characteristicso fD r .P I A Sa r ew h a tm a k e
Dr. PIAS distinct from other existing databases. 2P2IDB
and TIMBAL primarily focus on the structural aspects
of protein pockets and the chemical properties of PPI-
inhibiting ligands, respectively. The information on the
biological function of a protein is also essential for
selecting drug target PPIs. Dr. PIAS stores functional
information on interacting proteins, such as disease
associations, pathways, GO terms, gene expression pro-
files, and paralogs. Therefore, Dr. PIAS can help
researchers select drug target PPIs by evaluating each
PPI from the three viewpoints of the tertiary structures
of protein/protein complexes, drugs/chemicals relevant
to interacting proteins, and the biological roles of PPIs
in living cells. A cross reference of the three databases
can provide researchers with a synergistic power to
prompt studies on drug target PPIs and chemicals inhi-
biting them.
Many databases of PPIs have been published, all with
the purpose of collecting as many PPIs as possible from
the literature and already-published similar databases.
Table 4 List of PPIs assessed as potentially druggable for lung cancer
PPI Druggability score
Structural attributes Drug/chemical attributes Functional attributes All attributes
CREBBP/TP53 0.9747 0.2234 0.9682 0.9507
E2F1/RB1 0.6162 0.4677 0.9922 0.9402
E2F2/RB1 0.8452 0.4677 0.9964 0.9000
EGFR/TGFA 0.6832 0.7028 0.9957 0.9393
EP300/TP53 0.9747 0.2234 0.9214 0.9454
GRB2/GRB2 0.9327 0.2356 0.9838 0.9058
GRB2/VAV1 0.7431 0.2234 0.9978 0.9662
HRAS/RAF1 0.5453 0.3029 0.9973 0.9140
HRAS/RALGDS 0.9320 0.2234 0.9891 0.9152
HRAS/RASA1 0.7267 0.2234 0.9988 0.9459
HRAS/SOS2 0.8991 0.2234 0.9911 0.9293
NFKB1/NFKBIA 0.8607 0.8146 0.9993 0.9343
NFKB1/RELB 0.5218 0.8146 0.9868 0.9195
RAF1/RAP1A 0.8070 0.4380 0.9937 0.9154
TP53/TP53BP2 0.2102 0.2234 0.3776 0.9274
XIAP/CASP3 0.5897 0.3679 0.9998 0.9219
XIAP/CASP9 0.7910 0.2277 0.9954 0.9468
From the 116 PPIs searched in Dr. PIAS using the keywords and options, the PPIs having a druggability score of ≥0.9 in the ‘All attributes’ column are listed.
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Page 10 of 12The main purpose for developing Dr. PIAS was not to
merely collect PPI data but to select useful PPIs (in this
case, as potential drug targets) from the collected data.
In this sense, the design concept of Dr. PIAS is comple-
t e l yd i f f e r e n tf r o mt h a to fa l lo t h e rP P Id a t a b a s e sp u b -
lished to date.
Future development
The number of PPIs for which small molecule inhibitors
have been discovered has gradually increased over the
last decade. This trend will continue. As more informa-
tion on known drug target PPIs accumulates, our assess-
ment system based on information obtained from
known target PPIs will be improved. We will intensively
incorporate information on novel drug target PPIs to
make Dr. PIAS more useful for researchers focusing on
the development of PPI-inhibiting drugs. In addition,
PPI data and all omics information will be updated
every half year. The number of PPIs stored in Dr. PIAS
will rapidly increase due to the accumulation of PPI
data in public databases and in the literature.
Conclusions
Dr. PIAS is a database system aimed at assessing the
druggability of PPIs. Of the huge number of currently
unidentified PPIs, there could be many latent PPIs that
are highly druggable. Dr. PIAS will aid the efficient dis-
covery of these druggable PPIs from the continuously
growing amount of PPI data.
Availability and requirements
Dr. PIAS is available at http://asp.gridasp.net/drpias/
index.php. Academic non-profit users can freely
access all of the contents stored in Dr. PIAS without
paying a licensing fee. Commercial and for-profit
users must obtain a license to access Dr. PIAS by
paying a licensing fee to and entering into a license
agreement with Beyond Computing, Co. Ltd. and
PharmaDesign, Inc.
Additional material
Additional file 1: Supplementary tables. Table S1 lists the positive set
PPIs used in our SVM-based method to assess the druggability of PPIs.
Table S2 is the list of the attributes of PPIs used in the assessment. Table
S3 lists the PPIs satisfying the criteria set to search for potential drug
targets for lung cancer (see text). Table S4 lists the PPIs associated with
BCL-XL protein in Dr. PIAS.
List of abbreviations
Dr. PIAS: druggable protein-protein interaction assessment system; FDA:
United States Food and Drug Administration; GO: gene ontology; HIV:
human immunodeficiency virus; PPI: protein-protein interaction; SVM:
support vector machine.
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